# Angiolutions

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/angiolutions

- Industry: Medical Devices & Equipment
- Headquarters: Hannover, Germany
- Website: www.angiolutions.com
- Total disclosed funding: $1.5M
- Latest round: Seed (Feb 17, 2021)
- Investors on record: 3

## About

Angiolutions specializes in innovative medical technology, focusing on the development of advanced devices for treating abdominal aortic aneurysms (AAAs) with minimally invasive solutions for healthcare providers.Angiolutions is dedicated to the creation of a medical device specifically designed to address abdominal aortic aneurysms (AAAs). The company is headquartered in Hannover, Germany, and was co-founded by Isabel Schellinger and Uwe Raaz. In February 2021, Angiolutions raised EUR 1.200 mn in Seed funding from investors Friba Investment, High-Tech Gründerfonds, and NBank, which brought the total amount raised to EUR 1.200 mn and the current company valuation to EUR 3.345 mn.Angiolutions focuses on the development of a revolutionary medical device aimed at addressing abdominal aortic aneurysms (AAAs), a condition characterized by the progressive "ballooning" of the aorta. The core product leverages innovative technology to absorb aortic pulse waves, mechanically shielding the aneurysm and thereby halting its growth. This device represents a significant advancement in AAA therapy, as it is designed to be minimally invasive and provides a solution to a condition that currently lacks effective treatments to prevent progression. Angiolutions primarily targets healthcare providers, including hospitals and clinics, within the cardiovascular field, catering to the needs of both physicians and patients. The geographical markets for this product include Europe and North America, with a focus on regions where healthcare systems prioritize advanced vascular treatments.Revenue generation for Angiolutions is structured around partnerships with healthcare institutions and direct sales to clinics and hospitals. Their flagship product is part of a premium pricing model, reflecting the advanced technology and significant clinical benefits it offers. Transactions occur through direct procurement by hospitals, as well as potential collaborations with distributors specializing in medical devices. The company's revenue streams are bolstered by ongoing relationships with healthcare providers, who engage in bulk purchasing agreements or long-term contracts to ensure a supply of the device for ongoing patient care, facilitating a sustainable revenue model through consistent demand from the healthcare sector focused on innovative treatments for AAA.In February 2021, Angiolutions raised Seed funding from investors Friba Investment, High-Tech Gründerfonds, and NBank, which will be utilized to invest in research and development. The company plans to expand its product line with new devices aimed at addressing vascular health issues, with expected launches in the upcoming years. Additionally, Angiolutions is looking to enter new markets in Asia and expand its presence in North America by the end of 2023.

## Funding rounds

- Seed, Feb 17, 2021, $1.5M — High-Tech Gruenderfonds, NBank, Friba Investment

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed
- NBank — Seed
- Friba Investment — Seed